Withdrawn
This medicine is now withdrawn from use in the European Union.
Overview
The marketing authorisation for Allex has been withdrawn at the request of the marketing authorisation holder.
This EPAR was last updated on 31/12/2009
Authorisation details
| Product details | |
|---|---|
| Name |
Allex
|
| Agency product number |
EMEA/H/C/000312
|
| Active substance |
desloratadine
|
| International non-proprietary name (INN) or common name |
desloratadine
|
| Therapeutic area (MeSH) |
|
| Anatomical therapeutic chemical (ATC) code |
R06AX27
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Schering-Plough Europe
|
| Revision |
0
|
| Date of issue of marketing authorisation valid throughout the European Union |
15/01/2001
|
| Contact address |
SP Europe
Rue de Stalle, 73 B-1180 Bruxelles Belgium |
Product information
31/12/2009 Allex - EMEA/H/C/000312 -
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Pharmacotherapeutic group
Antihistamines for systemic use
Therapeutic indication
Therapeutic indication
Aerius is indicated for the relief of symptoms associated with:
- allergic rhinitis (see section 5.1)
- urticaria (see section 5.1)